<?xml version='1.0' encoding='utf-8'?>
<document id="24051055"><sentence text="The role of competitive binding to human serum albumin on efavirenz-warfarin interaction: a nuclear magnetic resonance study."><entity charOffset="58-67" id="DDI-PubMed.24051055.s1.e0" text="efavirenz" /></sentence><sentence text="The potential for co-prescription of the anti-human immunodeficiency virus (anti-HIV) drug efavirenz (EFV) and the oral anticoagulant warfarin (WAR) is currently high as EFV is a drug of choice for HIV type 1 infection and because cardiovascular disease is increasing among HIV-infected individuals"><entity charOffset="91-100" id="DDI-PubMed.24051055.s2.e0" text="efavirenz" /></sentence><sentence text=" However, clinical reports of EFV-WAR interaction, leading to WAR overdosing, call for elucidation of the mechanisms involved in this drug-drug interaction" /><sentence text=" Here we present the first report demonstrating competition of the two drugs for the same binding site of human serum albumin" /><sentence text=" Using ligand-based nuclear magnetic resonance experiments, this study proves that EFV has an effect on the concentration of free WAR" /><sentence text=" This previously unidentified EFV-WAR interaction represents a potential risk factor that should be taken into account when considering treatment options" /><sentence text=" " /></document>